Literature DB >> 29296942

Gene-edited pseudogene resurrection corrects p47phox-deficient chronic granulomatous disease.

Randall K Merling1, Douglas B Kuhns2, Colin L Sweeney1, Xiaolin Wu3, Sandra Burkett4, Jessica Chu1, Janet Lee1, Sherry Koontz1, Giovanni Di Pasquale5, Sandra A Afione5, John A Chiorini5, Elizabeth M Kang1, Uimook Choi1, Suk See De Ravin1, Harry L Malech1.   

Abstract

Pseudogenes are duplicated genes with mutations rendering them nonfunctional. For single-gene disorders with homologous pseudogenes, the pseudogene might be a target for genetic correction. Autosomal-recessive p47phox-deficient chronic granulomatous disease (p47-CGD) is a life-threatening immune deficiency caused by mutations in NCF1, a gene with 2 pseudogenes, NCF1B and NCF1C. The most common NCF1 mutation, a GT deletion (ΔGT) at the start of exon 2 (>90% of alleles), is constitutive to NCF1B and NCF1C. NCF1 ΔGT results in premature termination, undetectable protein expression, and defective production of antimicrobial superoxide in neutrophils. We examined strategies for p47-CGD gene correction using engineered zinc-finger nucleases targeting the exon 2 ΔGT in induced pluripotent stem cells or CD34+ hematopoietic stem cells derived from p47-CGD patients. Correction of ΔGT in NCF1 pseudogenes restores oxidase function in p47-CGD, providing the first demonstration that targeted restoration of pseudogene function can correct a monogenic disorder.

Entities:  

Year:  2016        PMID: 29296942      PMCID: PMC5727772          DOI: 10.1182/bloodadvances.2016001214

Source DB:  PubMed          Journal:  Blood Adv        ISSN: 2473-9529


  23 in total

1.  A genome-wide survey of human pseudogenes.

Authors:  David Torrents; Mikita Suyama; Evgeny Zdobnov; Peer Bork
Journal:  Genome Res       Date:  2003-12       Impact factor: 9.043

2.  Recombination within the human embryonic xi-globin locus: a common xi-xi chromosome produced by gene conversion of the psi xi gene.

Authors:  A V Hill; R D Nicholls; S L Thein; D R Higgs
Journal:  Cell       Date:  1985-10       Impact factor: 41.582

3.  Transgene-free iPSCs generated from small volume peripheral blood nonmobilized CD34+ cells.

Authors:  Randall K Merling; Colin L Sweeney; Uimook Choi; Suk See De Ravin; Timothy G Myers; Francisco Otaizo-Carrasquero; Jason Pan; Gilda Linton; Lifeng Chen; Sherry Koontz; Narda L Theobald; Harry L Malech
Journal:  Blood       Date:  2013-02-05       Impact factor: 22.113

4.  Generation of functionally mature neutrophils from induced pluripotent stem cells.

Authors:  Colin L Sweeney; Randall K Merling; Uimook Choi; Debra Long Priel; Douglas B Kuhns; Hongmei Wang; Harry L Malech
Journal:  Methods Mol Biol       Date:  2014

5.  Mutational analysis of patients with p47-phox-deficient chronic granulomatous disease: The significance of recombination events between the p47-phox gene (NCF1) and its highly homologous pseudogenes.

Authors:  N Vázquez; T Lehrnbecher; R Chen; B L Christensen; J I Gallin; H Malech; S Holland; S Zhu; S J Chanock
Journal:  Exp Hematol       Date:  2001-02       Impact factor: 3.084

6.  A copy number variation in human NCF1 and its pseudogenes.

Authors:  Tiffany Brunson; Qingwei Wang; Isfahan Chambers; Qing Song
Journal:  BMC Genet       Date:  2010-02-23       Impact factor: 2.797

7.  Therapeutic vulnerability of an in vivo model of alveolar soft part sarcoma (ASPS) to antiangiogenic therapy.

Authors:  David T Vistica; Melinda Hollingshead; Suzanne D Borgel; Susan Kenney; Luke H Stockwin; Mark Raffeld; David S Schrump; Sandra Burkett; Gary Stone; Donna O Butcher; Robert H Shoemaker
Journal:  J Pediatr Hematol Oncol       Date:  2009-08       Impact factor: 1.289

8.  The human T-cell receptor gamma variable pseudogene V10 is a distinctive marker of human speciation.

Authors:  X M Zhang; G Cathala; Z Soua; M P Lefranc; S Huck
Journal:  Immunogenetics       Date:  1996       Impact factor: 2.846

9.  In vitro molecular reconstitution of the respiratory burst in B lymphoblasts from p47-phox-deficient chronic granulomatous disease.

Authors:  B D Volpp; Y Lin
Journal:  J Clin Invest       Date:  1993-01       Impact factor: 14.808

10.  Homology-driven genome editing in hematopoietic stem and progenitor cells using ZFN mRNA and AAV6 donors.

Authors:  Jianbin Wang; Colin M Exline; Joshua J DeClercq; G Nicholas Llewellyn; Samuel B Hayward; Patrick Wai-Lun Li; David A Shivak; Richard T Surosky; Philip D Gregory; Michael C Holmes; Paula M Cannon
Journal:  Nat Biotechnol       Date:  2015-11-09       Impact factor: 54.908

View more
  15 in total

1.  Differential Transgene Silencing of Myeloid-Specific Promoters in the AAVS1 Safe Harbor Locus of Induced Pluripotent Stem Cell-Derived Myeloid Cells.

Authors:  Denise Klatt; Erica Cheng; Dirk Hoffmann; Giorgia Santilli; Adrian J Thrasher; Christian Brendel; Axel Schambach
Journal:  Hum Gene Ther       Date:  2020-01-23       Impact factor: 5.695

2.  NCF1 (p47phox)-deficient chronic granulomatous disease: comprehensive genetic and flow cytometric analysis.

Authors:  Douglas B Kuhns; Amy P Hsu; David Sun; Karen Lau; Danielle Fink; Paul Griffith; Da Wei Huang; Debra A Long Priel; Laura Mendez; Samantha Kreuzburg; Christa S Zerbe; Suk See De Ravin; Harry L Malech; Steven M Holland; Xiaolin Wu; John I Gallin
Journal:  Blood Adv       Date:  2019-01-22

Review 3.  Gene Editing in Human Haematopoietic Stem Cells for the Treatment of Primary Immunodeficiencies.

Authors:  Sameer Bahal; Klesti Karaxhuku; Giorgia Santilli
Journal:  Mol Diagn Ther       Date:  2022-10-14       Impact factor: 4.476

4.  Oxidants in Physiological Processes.

Authors:  Ulla G Knaus
Journal:  Handb Exp Pharmacol       Date:  2021

5.  CRISPR-targeted MAGT1 insertion restores XMEN patient hematopoietic stem cells and lymphocytes.

Authors:  Julie Brault; Taylor Liu; Ezekiel Bello; Siyuan Liu; Colin L Sweeney; Ronald J Meis; Sherry Koontz; Cristina Corsino; Uimook Choi; Guillaume Vayssiere; Marita Bosticardo; Kennichi Dowdell; Cicera R Lazzarotto; Aaron B Clark; Luigi D Notarangelo; Juan C Ravell; Michael J Lenardo; Benjamin P Kleinstiver; Shengdar Q Tsai; Xiaolin Wu; Gary A Dahl; Harry L Malech; Suk See De Ravin
Journal:  Blood       Date:  2021-12-30       Impact factor: 25.476

6.  Genetic Diagnostic Elucidation of a Patient With Multiorgan Granulomas, Facial Peculiarities, and Psychomotor Retardation.

Authors:  Daniel Soukup; Alma Kuechler; Joachim Roesler; Leopold Pichlmaier; Maximillian Eckerland; Margarete Olivier; Florian Stehling
Journal:  Front Genet       Date:  2018-09-27       Impact factor: 4.599

Review 7.  Genome editing: A perspective on the application of CRISPR/Cas9 to study human diseases (Review).

Authors:  Diana Raquel Rodríguez-Rodríguez; Ramiro Ramírez-Solís; Mario Alberto Garza-Elizondo; María De Lourdes Garza-Rodríguez; Hugo Alberto Barrera-Saldaña
Journal:  Int J Mol Med       Date:  2019-02-26       Impact factor: 4.101

8.  CRISPR-Directed Therapeutic Correction at the NCF1 Locus Is Challenged by Frequent Incidence of Chromosomal Deletions.

Authors:  Dominik Wrona; Oleksandr Pastukhov; Robert S Pritchard; Federica Raimondi; Joëlle Tchinda; Martin Jinek; Ulrich Siler; Janine Reichenbach
Journal:  Mol Ther Methods Clin Dev       Date:  2020-04-25       Impact factor: 6.698

Review 9.  Recent advances in understanding and treating chronic granulomatous disease.

Authors:  Andrew Gennery
Journal:  F1000Res       Date:  2017-08-11

10.  Targeted Repair of p47-CGD in iPSCs by CRISPR/Cas9: Functional Correction without Cleavage in the Highly Homologous Pseudogenes.

Authors:  Denise Klatt; Erica Cheng; Friederike Philipp; Anton Selich; Julia Dahlke; Reinhold E Schmidt; Juliane W Schott; Hildegard Büning; Dirk Hoffmann; Adrian J Thrasher; Axel Schambach
Journal:  Stem Cell Reports       Date:  2019-09-19       Impact factor: 7.765

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.